Recital 7, Regulation (EU) 2024/238

In forcesince 15 Jan 2024

Following this opinion and in order to further evaluate the safety of those three substances the interested business operators committed to provide further data that would allow a thorough assessment of the in vivo aneugenicity for these three substances [IOFI EFFA Letter DG Sante – EFSA Opinion 216 Rev2 (EFSA Journal (2022; 20(8) 7420)) – follow-up IOFI/EFFA letter: confirmation of follow-up testing and anticipated timings. Ares(2022)8489668].